Autologous CD4+CD25hiFoxP3+regulatory T cells - iReg Medical

Drug Profile

Autologous CD4+CD25hiFoxP3+regulatory T cells - iReg Medical

Latest Information Update: 11 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iReg Medical
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Transplant rejection

Most Recent Events

  • 11 Jul 2016 Preclinical development is ongoing in Sweden
  • 11 Jul 2016 Autologous CD4+CD25hiFoxP3+regulatory T cells - iReg Medical is available for licensing as of 11 Jul 2016. http://icell-science.com/
  • 31 Dec 2013 Preclinical trials in Transplant rejection (Prevention) in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top